Laborie Medical Technologies Corp. entered into an agreement to acquire JADA System of Organon & Co. (NYSE:OGN) for approximately $470 million on November 6, 2025. The purchase price consists of $440 million paid at closing and a milestone payment of up to $25 million subject to the achievement of certain 2026 revenue targets. As part of the agreement, approximately 100 employees are expected to transfer to Laborie.
Organon?s board of directors approved the transaction. The transaction is subject to closing conditions, including the appropriate involvement of employee representatives in certain markets outside of the U.S. and regulatory approvals. The expected completion of the transaction is in the first quarter of 2026. The net proceeds in the transaction will be applied to Organon?s debt reduction.
Guggenheim Capital, LLC acted as financial advisor for Laborie Medical Technologies Corp. Simpson Thacher & Bartlett LLP and Cooley LLP acted as legal advisors for Laborie Medical Technologies Corp. Goldman Sachs & Co. LLC acted as financial advisor for Organon & Co.
Laborie Medical Technologies Corp. completed the acquisition of JADA System of Organon & Co. (NYSE:OGN) on January 28, 2026.
Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions. Its portfolio also includes VTAMA (tapinarof) cream, 1%, a nonbiologic, non-steroidal topical therapy, for treatment of mild, moderate, and severe plaque psoriasis in adults.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
